timothy sykes logo

Stock News

OneMedNet Drives Revenue Growth with Strategic Partnerships and Subscriptions

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 2/28/2026, 8:11 am ET 2/28/2026, 8:11 am ET | 5 min 5 min read
OneMedNet Drives Revenue Growth with Strategic Partnerships and Subscriptions Thumbnail

OneMedNet Corp’s stocks have been trading up by 43.18 percent amid positively improved public sentiment.

Healthcare industry expert:

Analyst sentiment – positive

OneMedNet’s (ONMD) current financial metrics indicate significant performance challenges, with alarming profitability ratios such as an EBIT margin of -393.3% and a gross margin of -144%. Revenue declines further exacerbate the situation with a compounded three-year growth rate of -17.73%. The valuation measures are concerning, reflected in a price-to-sales ratio of 63.78 and negative book value per share (BVPS) of -0.08, indicating potential insolvency risks. Additionally, the return on assets at -69.02% underscores inefficient asset utilization, and a current ratio of 0.3 suggests liquidity issues. These indicators collectively paint a bleak picture, signaling substantial financial restructuring is required to salvage margins and improve operational efficiency.

From a technical standpoint, the recent price cadence reveals an upward trajectory, with notable volume spikes accompanying a price increase from $0.6212 to $1.01 over five trading days. This bullish momentum suggests strong investor sentiment, aligning with strategic announcements. Volume analysis indicates accumulation, particularly between the $0.70 and $1 mark, suggesting resistance at $1.17. Traders might consider a momentum strategy to capitalize on further positive news, maintaining positions above the $1 support level, while trimming exposure should the price retract below $0.99, indicating a weakening of the upward drive.

Recent developments highlight OneMedNet’s strategic pivot, with successful transitions to multi-year subscription contracts and substantial contracts, such as a notable partnership with ViuHealth. These catalysts indicate an operational inflection point, likely enhancing high-margin recurring revenues. The shift towards commercialization, now involving over 2,130 healthcare sites, positions ONMD ahead of sector benchmarks, particularly within real-world data markets. A strategic buy stance is advised, with anticipated support at $0.99 and resistance at $1.17, driven by aggressive expansion initiatives and strong market reception. Long-term prospects appear promising, contingent on successful execution of these commercial strategies.

Candlestick Chart

Weekly Update Feb 23 – Feb 27, 2026: On Saturday, February 28, 2026 OneMedNet Corp stock [NASDAQ: ONMD] is trending up by 43.18%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

OneMedNet Corp’s recent financials reveal a mixed bag but with promising inclinations towards revenue growth. Although ONMD’s stock closed at $1.01 on February 27, 2026, from an opening of $1.04, prior trading days showcased healthier price levels with peaks at $1.17. The strategic shift towards subscription services seems promising, placing ONMD on a potentially lucrative trajectory as evidenced by $2.79M in new contract bookings and advancements in data commercialization. Despite a current revenue of $643,000 along with a high price-to-sales ratio at 63.78, these figures must be carefully watched as ONMD continues to engage the rapidly growing healthcare data landscape.

More Breaking News

Key financial indicators highlight challenges such as a negative EBIT and EBITDA margin, pointing towards restructuring needs. However, the transition to subscription models might just offer relief by introducing stable revenue streams. Recent successes in multi-year contracts and partnerships forecast an optimistic outlook despite ONMD not logging positive earnings per share yet.

Conclusion

OneMedNet Corp is strategically forging ahead with tremendously promising initiatives in the healthcare data realm. While existing financial figures certainly indicate areas of concern, recent developments suggest a potentially lucrative turning point for the organization. By pivoting to lucrative long-term partnerships and commercializing data initiatives, ONMD is set to firmly position itself within the healthcare data market. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Sustained clarity in its financial strategy paired with these innovative strategies could see ONMD overcoming current financial hurdles to deliver profitable outcomes for traders. The importance of maintaining momentum and executing these strategies efficiently cannot be overstated as ONMD strives for a competitive edge.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”